


CLAIMS

What is claimed is:

1. A compound of Formula (I):



wherein:

R₁ is C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl, wherein the C₁₋₈ alkyl, C₃₋₆ cycloalkyl and C₁₋₆ haloalkyl groups are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, aryl, substituted aryl, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, heteroaryl, heterocyclyl, hydroxyl, nitro and thiol;

R₂, R₃ and R₄ are each independently selected from the group consisting of H, C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro and thiol; and

R₅ is H or C₁₋₆ alkyl; or

a pharmaceutically acceptable salt or a solvate thereof;

provided that:

- a) when R₅ is ethyl, and R₂, R₃ and R₄ are H then R₁ is not methyl or triphenylmethyl;
- b) when R₅ is n-pentyl, and R₂, R₃ and R₄ are H then R₁ is not n-butyl;
- c) when R₅ is methyl, and R₂, R₃ and R₄ are H then R₁ is not pyrrolidin-1-ylmethyl, 3-tert-butyl-2-hydroxy-5-methyl-benzyl, methyl, or dimethylaminomethyl;
- d) when R₅ is methyl, R₂ is carbomethoxy and R₃ and R₄ are both H then R₁ is not methyl;

e) when R_2 , R_3 , R_4 and R_5 are all H then R_1 is not 2-amino-2-carboxy-ethyl, pyrrolidin-1-ylmethyl, isopropyl, methyl, benzyl, n-butyl, or carboxymethyl; and

f) when R_2 , R_4 , and R_5 are all H and R_3 is methoxy then R_1 is not methyl.

2. A compound according to claim 1 wherein:

R_1 is C_{3-6} cycloalkyl or C_{1-6} haloalkyl, where each C_{3-6} cycloalkyl or C_{1-6} haloalkyl group is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C_{1-6} acyl, C_{1-6} acyloxy, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkylcarboxamido, C_{2-6} alkynyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylthio, C_{1-6} alkylureyl, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, carbo C_{1-6} alkoxy, carboxy, cyano, C_{3-6} cycloalkyl, C_{1-6} dialkylcarboxamido, halogen, C_{1-6} haloalkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkylsulfinyl, C_{1-6} haloalkylsulfonyl, C_{1-6} haloalkylthio, hydroxyl, nitro and thiol;

R_2 , R_3 and R_4 are each independently selected from the group consisting of H, C_{1-6} acyl, C_{1-6} acyloxy, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkylcarboxamido, C_{2-6} alkynyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylthio, C_{1-6} alkylureyl, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, carbo C_{1-6} alkoxy, carboxy, cyano, C_{3-6} cycloalkyl, C_{1-6} dialkylcarboxamido, halogen, C_{1-6} haloalkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkylsulfinyl, C_{1-6} haloalkylsulfonyl, C_{1-6} haloalkylthio, hydroxyl, nitro or thiol; and

R_5 is H or C_{1-6} alkyl; or a pharmaceutically acceptable salt or a solvate thereof.

3. The compound according to claim 1 or 2 wherein R_5 is C_{1-6} alkyl.

4. The compound according to claim 1 or 2 wherein R_5 is H.

5. The compound according to any one of claims 1 to 4 wherein R_2 , R_3 and R_4 are each independently H or halogen.

6. The compound according to any one of claims 1 to 4 wherein R_2 , R_3 and R_4 are each independently H or F.


7. The compound according to any one of claims 1 and 3 to 6 wherein R_1 is C_{1-8} alkyl optionally substituted with substituents selected from the group consisting of C_{2-6} alkenyl, C_{1-6} alkoxy, C_{2-6} alkynyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylthio, aryl, substituted aryl, C_{3-6} cycloalkyl, halogen, C_{1-6} haloalkoxy, C_{1-6} haloalkylsulfinyl, C_{1-6} haloalkylsulfonyl, C_{1-6} haloalkylthio, heteroaryl, heterocyclyl, and hydroxyl.

8. The compound according to any one of claims 1 and 3 to 6 wherein R₁ is selected from the group consisting of 2-butyl, 3-pentyl, 1-propyl, t-butyl, 1-butyl, 4-Methyl-pentyl, 3-methyl-butyl, 1,3-dimethyl-butyl, 3,3-dimethyl-butyl, 1-heptyl, ethyl, 2,2-dimethyl-propyl, and 1-pentyl.
9. The compound according to any one of claims 1 and 3 to 6 wherein R₁ is selected from the group consisting of 3-methoxy-benzyl, 4-methoxy-benzyl, 4-methoxy-phenyl ethyl, 3-methoxy-phenyl ethyl, 3,5-difluorobenzyl, and benzhydrl.
10. The compound according to any one of claims 1 and 3 to 6 wherein R₁ is selected from the group consisting of 3-isopropoxypropyl, tetrahydro-furan-2-ylmethyl, 2-methoxy-ethyl, 2-ethylsulfanyl-ethyl, 3-hydroxy-propyl, allyl, cyclopropylmethyl, but-2-ynyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2-ethoxy-ethyl, and 1,2-dimethyl-propyl.
11. The compound according to any one of claims 1 to 6 wherein R₁ is selected from the group consisting of cyclopentyl, cyclohexyl, cyclopropyl, and cyclobutyl.
12. The compound according to claim 1 selected from the group consisting of:
- 1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2'-Butyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Propyl-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(Tetrahydro-furan-2'-ylmethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;
 - 1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-[2'-(4''-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;
 - 1-[2'-(3''-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;
 - 1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 - 1-t-Butyl-1H-benzotriazole-5-carboxylic acid;

- 1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;
 1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
 1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
 1-Heptyl-1H-benzotriazole-5-carboxylic acid;
 5 1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 1-(2'-Hydroxy-1'-hydroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
 1-Ethyl-1H-benzotriazole-5-carboxylic acid;
 1-Pentyl-1H-benzotriazole-5-carboxylic acid;
 1-(2',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
 10 1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
 1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
 1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;
 1-Allyl-1H-benzotriazole-5-carboxylic acid;
 1-Butyl-1H-benzotriazole-5-carboxylic acid;
 15 1-(Cyclopropylmethyl)-1H-benzotriazole-5-carboxylic acid;
 1-(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;
 1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and
 1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or
 a pharmaceutically acceptable salt, solvate or hydrate thereof.

20

13. A pharmaceutical composition comprising a compound according to:
 a) Formula (I):



(I)

wherein:

- 25 R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl or C₁₋₆ haloalkyl group is optionally substituted with C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro or thiol;
 30

R₂, R₃ and R₄ are independently H, C₁₋₆ acyl, C₁₋₆ acyloxy, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarboxamido, C₂₋₆ alkynyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylureyl, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, carbo C₁₋₆ alkoxy, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₆ dialkylcarboxamido, halogen, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkylsulfinyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ haloalkylthio, hydroxyl, nitro or thiol; and

R₅ is H or C₁₋₆ alkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof; or

b) any one of claims 1 to 12; wherein said compound is in combination with a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 further comprising an agent selected from the group consisting of α -glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.

15. A compound according to any one of claims 1 to 12 for use in a method of treatment of the human or animal body by therapy.

16. A compound according to any one of claims 1 to 12 for use in a method of treatment of metabolic-related disorders.

17. A compound according to any one of claims 1 to 12 for use in a method of treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

18. A compound according to any one of claims 1 to 12 for use in a method of treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

19. A compound according to any one of claims 1 to 12 for use in a method of treatment of atherosclerosis.

20. A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 12.
- 5 21. A method according to claim 20 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
- 10 22. A method according to claim 20 wherein said metabolic-related disorder is atherosclerosis.
23. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder.
- 15 24. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
- 20 25. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of atherosclerosis.